Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).
about
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.Treating human autoimmune disease by depleting B cellsRituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathyAnti-B cell therapy (rituximab) in the treatment of autoimmune diseases.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?Current pharmacotherapy for the treatment of crescentic glomerulonephritis.Rituximab: applications in dermatology.Update on the use of biologics in primary systemic vasculitides.Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature.Successful rituximab therapy in a lupus patient with diffuse alveolar haemorrhage.Successful Treatment of Dual-Positive Anti-Myeloperoxidase and Anti-Glomerular Basement Membrane Antibody Vasculitis with Pulmonary-Renal Syndrome.N-Butyl-2-cyanoacrylate-based injectable and in situ-forming implants for efficient intratumoral chemotherapy.Rituximab in two cases of Goodpasture's syndrome.Rituximab therapy for primary glomerulonephritis: Report on two casesA unique way to treat Goodpasture's disease.The missing link between smoking and COPD autoreactivity?High-dose immunosuppression with autologous stem cell transplantation in severe refractory systemic lupus erythematosus.Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab).Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.Rationale and efficacy for the use of rituximab in paraneoplastic pemphigusUse of rituximab as an induction therapy in anti-glomerular basement-membrane disease
P2860
Q33365619-3D56CFF8-CEC6-4502-8BEA-6D7750135B82Q34848963-F24E3335-CC0A-459F-8732-F936F22F267CQ35310890-07DA7F78-44E0-43BB-A41B-B06175B8A87DQ36088058-873F29B1-385A-484E-939A-4C6A5DF15114Q36171750-20E2EC1C-475C-4899-B861-DC519C1457E8Q36504479-B796A6FC-84C9-4E59-94C7-E8A3260EBA61Q36623061-40CC28C2-94B9-4C30-B6DD-840787EC2148Q36623217-FB41A3EA-6D80-4320-A757-14FD1A8550EBQ37754811-CDA23E48-1638-46F2-AE44-A18772C4296DQ37807326-8FF067C7-B0F8-4844-A2C8-190A22D02D20Q37845011-DE057972-ADD8-488F-971A-A70872D10B14Q38343236-F1114834-0862-4908-9D8D-BC4B73031FEFQ38821071-17405375-0EF1-4A40-8A27-29C82533F6E7Q40320110-03D67CAE-70F5-44AE-B62B-B70BC303C0FBQ41036642-1FBC26E1-14B9-4F25-97E2-EE1B546253E3Q41986115-75F4BFFF-E958-435B-8C05-6F1FA8685AB2Q42958676-C4954884-959C-44EE-A52C-3B60FFD4E933Q44470266-B5578F4A-19D5-4809-B49A-E3F6BD5EA1C2Q44489047-A5C5F782-F7F3-41B6-B5A6-F103AD42B8E8Q48301180-17969307-B6FC-4C31-8012-064CF1FEFA15Q58482127-E8C3B6CE-0407-4D79-B479-BA788D9695A6Q58711212-F0F86B32-F265-4B3A-8AA1-EA17A766DCC2
P2860
Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Treatment of refractory antibo ...... noclonal antibody (rituximab).
@ast
Treatment of refractory antibo ...... noclonal antibody (rituximab).
@en
type
label
Treatment of refractory antibo ...... noclonal antibody (rituximab).
@ast
Treatment of refractory antibo ...... noclonal antibody (rituximab).
@en
prefLabel
Treatment of refractory antibo ...... noclonal antibody (rituximab).
@ast
Treatment of refractory antibo ...... noclonal antibody (rituximab).
@en
P2093
P356
P1476
Treatment of refractory antibo ...... noclonal antibody (rituximab).
@en
P2093
P304
P356
10.1136/ARD.61.10.922
P407
P577
2002-10-01T00:00:00Z